oral glp-1 agonist approved GLP-1: A Needle-Free Solution for Weight Loss New GLP-1 Guidelines for Type

doi: 10.1016/j.dsx.2018.03.002 44 McCleanPLHlscherC

Furthermore, some were these drugs were associated with potential undesirable effects, such as the risk of heart failure or fractures (complications that are especially prevalent in patients with CKD), this is the case of thiazolidinediones, and the use of sulfonylureas and insulin are associated with weight gain or the risk of hypoglycemia

Pramlintide is an amylin analogue licensed for type 1 diabetes in the US but currently very few people are treated with it [4], and the risk of severe hypoglycaemia remains a barrier to its approval in the UK and Europe [5]

A study published last summer by JAMA Oncology looked at GLP-1 use and 14 obesity-related cancers and found that while the weight-loss drug lowered the risk of most cancers, there was a nonsignificant increased risk of kidney cancer particularly among people younger than 65

Depending on your health profile and what your assigned clinician decides is the right fit, you may also be prescribed brand-name versions: Ozempic, Wegovy, Mounjaro, or Zepbound

Funding This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number: NRF-2019R1F1A1054111 (JS), NRF-2019R1I1A3A01058861 (OK), and NRF-2018R1A2B6001104 (Y-KK)